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OBJECTIVES We sought to examine the role of the pro-inflammatory cytokine, interleukin-1-beta (IL-1),
in the process of left ventricular (LV) remodeling in the early phase after myocardial
infarction (MI).
BACKGROUND Studies have shown that pro-inflammatory cytokines are closely related to the progression of
LV remodeling after MI.
METHODS Mice underwent coronary artery ligation, and the time course of LV remodeling was followed
up to 20 weeks. The gene expression level of IL-1 was examined. In a second set of
experiments, the mice underwent coronary artery ligation followed by treatment with
anti–IL-1 antibody (100 g, intravenously), versus control immunoglobulin G (100 g,
intravenously) immediately after the operation.
RESULTS Rapid hypertrophy of noninfarcted myocardium was observed by four weeks, and interstitial
fibrosis progressed steadily up to 20 weeks. Anti–IL-1 treatment increased the occurrence
of ventricular rupture and suppressed collagen accumulation in the infarct-related area. At
four and eight weeks after the operation, total heart weight and LV end-diastolic dimension
were significantly greater in the anti–IL-1-treated mice than in the other groups. In the
infarct-related area, collagen accumulation was suppressed, whereas in the noninfarcted area,
pro-collagen gene expression levels, particularly type III, were decreased in the anti–IL-1-
treated mice.
CONCLUSIONS Anti–IL-1 treatment suppressed pro-collagen gene expression and delayed wound healing
mechanisms—properties that are likely to lead to progression of LV remodeling. In the acute
phase of MI, IL-1 appears to play a protective role. (J Am Coll Cardiol 2001;38:1546–53)
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Myocardial infarction (MI) is followed by distinct changes,
including hypertrophy of the noninfarcted myocardium,
interstitial fibrosis and increases in left ventricular (LV)
chamber dimensions, known as LV remodeling. The course
of LV remodeling appears to be dependent on the size of
the infarct, as well as on the load placed on the myocardium
(1–3). Excessive progression of LV remodeling alters the
structure of the heart and impairs its pumping function and
blood supply; it is also associated with an increased risk of
congestive heart failure (1,2,4,5). Prevention of excessive
LV remodeling is one of the most important issues today
(6–8).
High blood levels of the pro-inflammatory cytokines,
interleukin-1-beta (IL-1) and tumor necrosis factor-alpha
(TNF-), have been observed after MI (9–11), and these
cytokines are suspected to play an important role in the
pathophysiology of LV remodeling (3,12,13). Recent stud-
ies have demonstrated that IL-1 and TNF- induce
myocyte hypertrophy in vitro (14–16) and hypothesized
that they promote tissue fibrosis in vivo (12,16,17). In the
rat, upregulation gene expression levels of these cytokines
persist up to the chronic phase of MI. Furthermore, levels of
IL-1 are related to the degree of interstitial fibrosis (12).
Therefore, we have hypothesized that pro-inflammatory
cytokines, particularly IL-1, are major promoting factors
of LV remodeling and that its progression could be atten-
uated by anti–IL-1 treatment.
The present study was designed to examine the role of
IL-1 and the effects of anti–IL-1-neutralizing antibody
treatment in the process of LV remodeling. The time course
of LV remodeling was first examined in mice with large
MIs.
METHODS
The investigation conforms with the Guide for the Care
and Use of Laboratory Animals, published by the National
Institutes of Health (NIH), Bethesda, Maryland (NIH
Publication no. 85-23, revised 1996).
Experiment 1. MICE. The experiments were performed in
eight- to nine-week-old male C57BL/6 mice, weighing
between 24 and 27 g, obtained from the Shizuoka Agricul-
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tural Cooperation Association (Shizuoka, Japan); they were
housed in stainless-steel cages with a controlled 12-h
light/dark cycle and given access to standard mouse chow
and water.
MI MODEL AND INFARCT SIZE. Myocardial infarction was
induced according to previously described methods, with
minor modifications using the microsurgery technique (18).
In brief, the animals were intraperitoneally anesthetized
with a mixture of ketamine hydrochloride (50 mg/kg) and
xylazine (10 mg/kg) and transtracheally intubated. Ventila-
tion was performed with an artificial ventilator, using room
air at 70 cycles/min and a tidal volume of 0.6 ml. The heart
was exposed through an anterior thoracotomy, and the
proximal left anterior coronary artery was ligated with a 7-0
silk suture. Mice that died within 24 h after the operation
were excluded from the analysis. The ischemic area was
measured 24 h after the operation. Five mice were anesthe-
tized as described earlier, and the chest wall was removed.
Then, 0.2 ml of 1% Evans blue dye was injected into the
ascending aorta; the heart was harvested and sliced trans-
versely into four slices perpendicular to the long axis of the
LV; and the ischemic area was separated from the nonisch-
emic area of the LV after the outlines of the Evans blue
staining. Infarct size was calculated from the ratio of the
weights of ischemic versus nonischemic areas. Sham-
operated mice underwent the same procedure, except for
ligation of the coronary artery.
EXPERIMENTAL DESIGN. The time course of LV remodel-
ing was followed at 1 and 3 days and at 1, 2, 4, 8, 12 and 20
weeks after the operation. At each time point, three to five
mice were superficially anesthetized with ether, and trans-
thoracic echocardiography (TTE) was performed to mea-
sure the LV end-diastolic dimension (LVEDD). After
TTE, the hearts were harvested. Mice without large MIs
involving the entire free wall and apex of the LV, which was
easily distinguishable by the changes of color of the myo-
cardium or wall thinning in the infarct-related area, were
excluded from the analysis due to technical failure. The
hearts were excised, halved along the ventricular short axis
and weighed. The cephalad halves were embedded in
paraffin for histologic examination, and the caudal halves
were snap-frozen at 70°C until ribonucleic acid (RNA)
extraction. Cardiomyocyte diameter was histologically ex-
amined using a computerized morphometric analysis system
(Polaroid PDMCD Ie, NIH Image 1.61), as described
previously (12). Interstitial collagen deposition levels were
quantified using a digital image analyzer (LUSEX 3, Nikon,
Tokyo, Japan). In brief, collagen matrix was discriminated
by Sirius red F3BA staining, and slide images were obtained
of the noninfarcted interventricular septum at a 400
magnification. Twenty fields per section were scanned and
computerized with a LUSEX 3 digital image analyzer on
the basis of the red staining of the collagen. Volume
collagen fraction was calculated as the sum of all connective
tissue areas divided by the total area of the image (12).
GENE EXPRESSION LEVEL OF IL-1. Additional experimen-
tal groups—1-, 3-, 6- and 12-h groups of three mice of
each—were made to examine the IL-1 gene expression
levels in the acute phase of MI. The infarct-related and
noninfarcted areas of the caudal parts of the heart were
divided; total RNA was extracted; and complementary
deoxyribonucleic acid was synthesized as previously de-
scribed (19). At each time point, gene expression levels of
IL-1 were measured in three mice by the real-time
quantitative reverse transcription polymerase chain reaction
(RT-PCR) method. The PCR primers and probe of IL-1
were purchased from PE Biosystems (Foster, California).
The gene expression level of GAPDH was quantified using
the following forward (F) and reverse (R) oligonucleotides
and probes (P) with fluorescent dye and quencher—F:
5-TTCACCACCATGGAGAAGGC-3 ; R: 5-
GGCATGGACTGTGGTCATGA-3; and P: 5-Fam-
TGCATCCTGCACCACCAACTGCTTAG-Tamura-
3. The values were averaged and expressed relative to the
increases in GAPDH.
Experiment 2. ANTI–IL-1 TREATMENTS. The mice were
randomized into three treatment groups: anti–IL-1 anti-
body, control immunoglobulin G (IgG) or the vehicle
(phosphate-buffered saline [PBS]). The sham-operated
mice were treated with control IgG. Hamster anti-mouse
IL-1 monoclonal antibody and control IgG, both from
Genzyme (Cambridge, Massachusetts) (20), were diluted
with PBS in a final volume of 200 l and injected into the
tail vein immediately after coronary ligation in doses of
100 g of antibody per mouse. This anti–IL-1 antibody
recognizes the IL-1 precursor and the mature secreted
form of mouse IL-1. No detectable cross reactivity was
observed with mouse IL-1, TNF- or interferon-gamma.
Treatment with the vehicle was administered intraperitone-
ally immediately after coronary artery ligation.
BLOOD PRESSURE. To estimate the effects of each treatment
on hemodynamic loading, blood pressure was measured
three days after the operation in three mice from each
treatment group, as described previously (21). Immediately
after the studies, the hearts were harvested and examined
histologically, and RNA was extracted, as described earlier.
Abbreviations and Acronyms
IgG  immunoglobulin G
IL-1  interleukin-1-beta
LV  left ventricular
LVEDD  left ventricular end-diastolic dimension
MI  myocardial infarction
PBS  phosphate-buffered saline
PCR  polymerase chain reaction
RNA  ribonucleic acid
RT  reverse transcription
TNF-  tumor necrosis factor-alpha
TTE  transthoracic echocardiography
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HEART DIMENSIONS AND WEIGHT MEASUREMENTS. Trans-
thoracic echocardiography was performed at one, four and
eight weeks after the operation. Immediately after the
studies, the hearts were excised, halved along the ventricular
short axis and weighed. The hearts were examined histo-
logically, and RNA was extracted, as described earlier.
COLLAGEN ACCUMULATION IN THE INFARCT-RELATED
AREA. Three days and one week after the operation, the hearts
of four mice were harvested, stained with hematoxylin-eosin
and Sirius red. The amount of collagen deposition in the
infarct-related area was measured, as described earlier.
QUANTIFICATION OF GENE EXPRESSION LEVELS. Addi-
tional study groups—one-day groups—were made to assess
the effect of the treatment in the early phase. We examined
the gene expression levels of types I and III pro-collagen by
real-time quantitative RT-PCR at one and three days and
one week after the operation in the noninfarcted area of four
mice from each group, using the following forward (F) and
reverse (R) oligonucleotides and probes (P) with fluorescent
dye and quencher—pro--2(I)-collagen: F: 5-GAGG-
ACACCCCTTCTACGTTGTA-3; R: 5-CAGTC-
CAACAAGCATGTCTGGT-3; and P: 5-Fam-
CAAACTGGCTGCCACCATTGATAGTCTCTC-
Tamura-3; and pro--1(III)-collagen: F: 5-TTACT-
CCTCCACAGGTCACCTCTC-3; R: 5-TATGAAT-
CAGGCAGCCGCT-3; and P: 5-Fam-AACCA-
GCCCGGATGTTCTCAGTGCTT-Tamura-3. Each
primer was designed to amplify the specific sequence of each
target gene. The values were averaged and expressed relative
to the increases in GAPDH.
STATISTICAL ANALYSIS. The variables of LV remodeling
(Fig. 1) are reported as the mean value  SD. Gene
expression levels were examined in three mice of each group
and expressed as the mean value  SEM. Other data are
expressed as the mean value  SD. One-way analysis of
variance with the Fisher protected least significant difference
test was used for statistical comparisons. The interaction
between four groups and the time course was tested for each
measure and found to be significant at a level of 0.05.
RESULTS
Experiment 1. MI. Coronary artery ligation was performed
in 197 male C57BL/6 mice. The mean operation time was
30 min per mouse. The perioperative mortality rate,
within 24 h after the operation, was 47% (92 mice), and 17
additional mice died of ventricular rupture between five and
Figure 1. Time course of left ventricular remodeling. See text for details. d  days; LVEDd  left ventricular end-diastolic dimension; MI  myocardial
infarction; W  weeks; *p  0.05; †p  0.01; **p  0.05 vs. sham-operated mice; ††p  0.01 vs. sham-operated mice.
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seven days after coronary artery occlusion (Table 1). Five
mice were sacrificed to measure infarct size, as described
previously (18). The infarct involved the entire LV free wall
and apex, representing 57% of the LV, and variability was
minimal (SD 4.2%). All sham-operated mice survived
through the study interval (Fig. 2, Table 1).
TIME COURSE OF LV REMODELING. The time course of LV
remodeling was examined by the changes in LVEDD, total
heart weight, cardiomyocyte diameter and interstitial collagen
deposition level (Figs. 1 and 2). Twenty-four hours after the
operation, the mean heart weight in the MI group was slightly
lower than that in the sham-operated group and, by four
weeks, had increased markedly (Fig. 1A). Twenty-four hours
after the operation, LVEDD was 3.4  1.4 mm in the study
group, versus 3.44  0.55 mm in the sham-operated mice. A
rapid increase in LVEDD was observed in the mice with MI
by four weeks after the operation (Figs. 1B, 2A and 2B). The
changes in cardiomyocyte diameter paralleled those of total
heart weight (Fig. 1C). Collagen deposition in the nonin-
farcted area of the hearts increased gradually from 0.64 
0.27% at baseline to 9.38  0.63% at 20 weeks after coronary
occlusion. In contrast, no increase in collagen deposition was
observed in the sham-operated mice (Figs. 1D and 2C).
GENE EXPRESSION LEVEL OF IL-1. A rapid increase in the
gene expression level of IL-1, peaking at 6 h after coronary
artery occlusion, was observed in the infarct-related area,
followed by a prompt decrease. In the noninfarcted area,
persistent gene expression of IL-1 was observed as late as
12 weeks after the operation (Fig. 3). On the basis of these
results, treatment was initiated immediately after coronary
ligation in Experiment 2.
Experiment 2. EFFECTS OF ANTI–IL-1 TREATMENT ON LV
REMODELING. Mice in the one-day and three-days groups
were excluded from the count, because ventricular rupture
occurred between five and seven days after the operation in
this model. It is particularly noteworthy that nine mice
treated with anti–IL-1 died of ventricular rupture, as
compared with two mice in the control (IgG-treated) group
and three mice in the vehicle-treated group. There was no
significant difference in the systolic blood pressure levels
measured among the various treatment groups at three days
after the operation (Table 2).
HEART WEIGHT AND LVEDD. There were no significant
differences in mean heart weight and LVEDD between the
vehicle-treated and control (IgG-treated) groups. Mice
treated with anti–IL-1 antibody had an increase in total
heart weight and LVEDD, which continued up to eight
weeks (Fig. 4). These results indicate that anti–IL-1
treatment in the acute phase of MI promoted LV dilation
and hypertrophy of the noninfarcted myocardium.
COLLAGEN ACCUMULATION IN THE INFARCT-RELATED
AREA AND PRO-COLLAGEN GENE EXPRESSION LEVELS.
Wound healing was evaluated by the degree of collagen
accumulation in the infarct-related area. At four and eight
weeks after the operation, the infarct-related area was almost
completely replaced by fibrous scar (Fig. 2A), so the wound
healing process was evaluated at three days and one week after
the operation. One week after coronary ligation, treatment
with anti–IL-1 antibody had significantly inhibited collagen
accumulation. There was no significant difference between the
control (IgG-treated) and vehicle-treated mice (Fig. 5). At the
same time, anti–IL-1 treatment demonstrated an inhibitory
effect on collagen gene expression in the noninfarcted area,
particularly on type III, which persisted beyond one week after
treatment. There was no significant difference between the
vehicle-treated and control (IgG-treated) mice (Fig. 5).
DISCUSSION
LV remodeling after MI in mice. This study describes the
time course of LV remodeling after MI in mice. In this
model, LV dilation was prominent within one week, and
cardiomyocyte hypertrophy was apparent just three days
after coronary occlusion. The interstitial fibrotic changes
continued for up to 20 weeks after the operation. Overall,
the model demonstrated the typical LV remodeling char-
acteristics that follow MI. These results prompted us to
examine changes at one week, the time of early remodeling,
at four weeks, the transition to chronic remodeling, and at
eight weeks, during chronic remodeling.
The role of cytokine in LV remodeling after MI. Cyto-
kines play pathogenic roles in a variety of inflammatory
diseases (22–24). Interleukin-1 and TNF-, in particular,
are suspected to play an important role in LV remodeling
(9,12,25). These pro-inflammatory cytokines promote myo-
cyte hypertrophy in vitro, and persistent gene expression can
be observed in the noninfarcted myocardium (12,26,27).
Interleukin-1, in particular, is closely associated with
Table 1. Comparison of Surgical Outcomes and Survival







Mortality within 24 h 92 (46.7%) 0 (0%)
Causes of death within 24 h
Pneumothorax 12 0
Acute heart failure 80 0
Operative success 105 (53.3%) 32 (100%)
Causes of death or sacrifice
beyond 24 h
Ventricular rupture 17 0
Heart failure 25 0
Sacrifice 63* 32
*Twenty-nine mice were excluded. Operative success was judged 24 h after the
operation. All sham-operated mice survived to the end of each study point. One
hundred ninety-seven mice received coronary occlusion. After coronary occlusion, 12
mice died of pneumothorax immediately after the operation, and 80 mice died within
24 h. One hundred five mice survived beyond 24 h. Among them, 17 died of
ventricular rupture between five and seven days after the operation (11 mice on day 5,
4 on day 6 and 2 on day 7). Twenty-five mice probably died of heart failure.
Twenty-nine mice that did not have a large infarction involving the entire free wall
and apex of the LV were excluded from experiment due to technical failure at the time
of sacrifice.
MI  myocardial infarction.
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Figure 2. Myocardial infarction (MI) in mice. (A) Evolution of representative serial sections of the hearts. Mice without extensive MI involving all of the free wall
and apex of the left ventricular (LV) were excluded from the analysis. Note the remarkable dilation of the LV cavity and hypertrophy of the noninfarcted
myocardium. Left ventricular dilation and hypertrophy were observed as early as four weeks after the operation. (B) The transthoracic echocardiography study. Note
the marked increase in LV end-diastolic dimension, as compared with that in the sham-operated mice. (C) Collagen staining. Note the scar formation in the
infarct-related area and the abundant collagen deposition in the interstitial space 12 weeks after coronary ligation, as compared with that in the sham-operated mice
(magnification 200).
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fibrosis after MI (12). We therefore hypothesized that
anti–IL-1 treatment would effectively inhibit the progres-
sion of LV remodeling. Interleukin-1 gene expression
increased rapidly after MI. To obtain specific suppression of
IL-1 bioactivity, a dose of monoclonal anti–IL-1-
neutralizing antibody was administered intravenously, im-
mediately after coronary ligation (28).
The effect of anti–IL-1 antibody treatment on wound
healing and LV remodeling. To our surprise, anti–IL-1
treatment in the acute phase of MI increased the occurrence
of ventricular rupture, promoted LV dilation and increased
total heart weight. The exact mechanism of this phenome-
non remains to be clarified. However, it is clear that IL-1
plays a protective role in the acute phase of MI.
In the process of LV remodeling, wound healing re-
sponses that result in fibrous tissue formation develop in the
affected ventricle, at the site of MI (1,2). Previous studies
suggest that collagen deposition after MI is important to
preserve ventricular architecture and function, and that a
low infarct collagen content is associated with more pro-
nounced remodeling and greater ventricular dilation (29–
32). It seems reasonable to hypothesize that fibrosis taking
place in the area with acute infarction is needed to prevent
the development of remodeling. Anti–IL-1 treatment was
associated with less collagen deposition in the infarct-
related area, which means a delay in wound healing and
suppression of pro-collagen gene expression in the nonin-
farcted area. Anti–IL-1 treatment is suspected to strongly
interfere with this response, resulting in an increase in the
incidence of ventricular rupture and in rapid LV dilation.
Figure 3. Gene expression levels of interleukin-1 (IL-1) were examined in three mice at each point by real-time quantitative reverse transcription-
polymerase chain reaction. A rapid increase in IL-1 gene expression level, peaking at 6 h, was observed in the infarct-related area, and decreased thereafter.
In the noninfarcted area, gene expression levels remained upregulated at 12 weeks after the operation. GADPH  glyceraldehyde-3-phosphate
dehydrogenase; h(s)  hour(s); ds  days; w(s)  week(s).
Table 2. Study Schedule, Mortality Distribution and Three-Day Blood Pressure Measurements
of the Various Treatment Groups





(G) (n  32)
Anti–IL-1





Mortality within 24 h 11 14 10 0
Operative success 21 (65.6%) 30 (68.2%) 24 (70.6%) 12 (100%)
Exclusion (technical failure)* 3 2 3 0
Causes of death
Ventricular rupture 2 9† 3‡ 0
Heart failure 4 5 6 0
Sacrifice
1 week 4 (0) 4 (0) 5 (1) 4 (0)
4 weeks 5 (1) 5 (1) 6 (2) 4 (0)
8 weeks 6 (2) 7 (1) 4 (0) 4 (0)
Systolic blood pressure
(day 3, n  3 of each)
89.3  1.15 88  2.0 88  2.0 93.3  1.15
*Data are presented as the mean number of mice excluded from the experiment due to technical failure. Other data are presented
as the number (%) of mice or mean value  SD. †p  0.05 vs. G. ‡p  NS vs. G. Operative success was judged 24 h after the
operation. There was no significant difference in the operation success rate according to the antibody treatment. It is noteworthy
that nine mice treated with anti–IL-1 antibody died of ventricular rupture during the follow-up period. In this experiment, no
mouse died of pneumothorax. There was no significant difference in systolic blood pressure among the study groups.
IgG  immunoglobulin G; IL  interleukin; MI  myocardial infarction.
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The pathophysiologic differences in the acute and
chronic phases after MI. The role of anti–IL-1 treat-
ment in late remodeling remains to be clarified. It has been
observed that, in the chronic phase of MI in the rat, IL-1
is closely associated with interstitial fibrosis in the nonin-
farcted area (12). Continued remodeling of the noninfarcted
area, with collagen deposition and fibrosis, has been shown
in rats and humans (33,34), and a close correlation between
myocardial stiffness and the amount of interstitial fibrosis
has been reported (35). In this murine model, gene expres-
Figure 4. Effect of anti-interleukin-1 (IL-1) treatment (monoclonal antibody) on the progression of left ventricular (LV) remodeling. Neutralization of
IL-1 in the acute phase of myocardial infarction significantly increased total heart weight and LV end-diastolic dimension (LVEDD). There was no
significant difference between the vehicle-treated and control (immunoglobulin G [IgG]-treated) groups (four mice in each). n.s.  not significant.
Figure 5. Effect of anti-interleukin-1 (IL-1) antibody treatment on infarct healing and pro-collagen gene expression. At three days and one week after
the operation, collagen accumulation in the infarct-related myocardium was measured as described in the text. Anti–IL-1 treatment inhibited collagen
accumulation in the infarct-related area, which caused a delay in wound healing. Gene expression of type III pro-collagen was suppressed by anti–IL-1
treatment by one and three days and one week after the operation. There was no significant difference between the vehicle-treated and control
(immunoglobulin G [IgG]-treated) groups (four mice in each). Ab  antibody; Col I and III  collagen type I and III, respectively; GADPH 
glyceraldehyde-3-phosphate dehydrogenase; n.s.  not significant.
1552 Hwang et al. JACC Vol. 38, No. 5, 2001
Interleukin-1 and LV Remodeling November 1, 2001:1546–53
sion of IL-1 and progression of interstitial fibrosis persist
in the chronic phase, and anti–IL-1 treatment suppressed
the gene expression of type III pro-collagen in the nonin-
farcted area. Persistent activation in the chronic phase is
suspected to promote excessive interstitial fibrosis, leading
to impairment of pumping function.
Conclusions. Distinct differences seem to exist between
the acute and chronic phases of MI in the pathogenesis of
LV remodeling. The treatment should be adjusted accord-
ing to the characteristics of its evolution. In the acute phase,
wound healing should be facilitated, whereas in the chronic
phase, the inflammatory response should be suppressed.
Interleukin-1 is an important therapeutic target in the
process of LV remodeling.
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